Psilocybin Slows Down Human Reaction Times and Impairs Executive Function During the Acute Phase of Use

Why It Matters

The findings highlight safety considerations for emerging psychedelic therapies, indicating patients should avoid activities requiring rapid responses while the drug is active.

Key Takeaways

• Reaction times increase linearly with psilocybin dose.
• Working memory remains more resilient than basic attention.
• Accuracy changes are statistically insignificant across doses.
• Cognitive slowing persists throughout acute window, regardless of timing.
• Publication bias may overstate magnitude of slowing.

Pulse Analysis

As psychedelic compounds move from experimental labs into therapeutic pipelines, understanding their immediate cognitive footprint becomes a regulatory priority. The recent meta‑analysis of psilocybin’s acute effects reveals a clear dose‑response relationship for reaction time, suggesting that even modest doses can impair the brain’s traffic‑control system. This slowdown is most pronounced in tasks that blend sensory input, motor output, and attention, while pure working‑memory operations show relative resilience. Such nuances inform clinicians about the specific cognitive domains that may be compromised during treatment sessions.

The mechanisms behind the observed delays likely involve a triad of sensory‑motor lag, altered baseline attention, and dual‑task interference from the intense subjective experience of a psychedelic trip. When patients are asked to perform standard laboratory tests while navigating vivid perceptual changes, mental resources are split, leading to slower responses. Consequently, medical protocols must enforce strict supervision, prohibiting activities like driving or operating machinery until the drug’s plasma levels subside, typically beyond the 180‑minute peak window.

Future research should pivot toward ecologically valid assessments that mirror real‑world demands, such as simulated driving or complex decision‑making scenarios, to differentiate true cognitive impairment from reduced test motivation. Moreover, longitudinal studies are needed to reconcile acute slowing with reported long‑term cognitive benefits of psilocybin therapy. Addressing publication bias and improving blinding techniques will sharpen effect size estimates, ultimately guiding evidence‑based guidelines for safe, effective psychedelic integration into mental‑health care.